Tissue Engineering Part A · 2017 · 76 citations · 18 references
EngineeringBioengineeringCardiologyRegenerative MedicineStem Cell BiologyTissue EngineeringBiomaterials For Tissue EngineeringCardiac PhysiologyCardiac Tissue EngineeringPluripotent Stem CellsTissue Engineering ScaffoldsTissue Engineering With Stem CellsEngineered Heart TissueInduced Pluripotent Stem CellsMagnetic-activated Cell SortingMyocardial Infarction ModelsMyocardial RegenerationMyocardial Tissue EngineeringScaffold-free Tissue EngineeringStem Cell-derived Cardiomyocytes
Although engineered cardiac tissues (ECTs) derived from induced pluripotent stem cells (iPSCs) are promising for myocardial regenerative therapy, the appropriate ratio of cardiomyocytes to non-cardiomyocytes is not fully understood. Here, we determined whether ECT-cell content is a key determinant of its structure/function, thereby affecting ECT therapeutic potential for advanced heart failure. Scaffold-free ECTs containing different ratios (25%, 50%, 70%, or 90%) of iPSC-derived cardiomyocytes were generated by magnetic-activated cell sorting by using cardiac-specific markers. Notably, ECTs showed synchronized spontaneous beating when cardiomyocytes constituted ≥50% of total cells, with the electrical-conduction velocity increasing depending on cardiomyocyte ratio; however, ECTs containing 90% cardiomyocytes failed to form stable structures. ECTs containing 25% or 50% cardiomyocytes predominantly expressed collagen and fibronectin, whereas ECTs containing 70% cardiomyocytes predominantly expressed laminin and exhibited the highest contractile/relaxation properties. Furthermore, transplantation of ECTs containing 50% or 70% cardiomyocytes into a rat chronic myocardial infarction model led to a more profound functional recovery as compared with controls. Notably, transplanted ECTs showed electrical synchronization with the native heart under Langendorff perfusion. Collectively, these results indicate that the quantity of non-cardiomyocytes is critical in generating functional iPSC-derived ECTs as grafts for cardiac-regeneration therapy, with ECTs containing 50-70% cardiomyocytes exhibiting stable structures and increased cardiotherapeutic potential.
18
Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy
Adam Williams, Barry Trachtenberg, Darcy L. Velazquez et al. · Circulation Research · 2011 · 317 citations · Full text
Medicine, Cardiology, Cell Therapy +14